Management of Pediatric Eosinophilic Esophagitis: Current Therapies, Emerging Treatments, and Future Directions—A Narrative Review
Pharmaceuticals · 26.10.2026 · 19 (11) · 1685
DOI: 10.3390/ph19111685 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 26.10.2026. Verfasst von Marco Natale und 4 weiteren Autor:innen. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disease characterized by esophageal dysfunction and eosinophil-predominant inflammation. Its increasing recognition in children and risk of progressive remodeling demand effective, sustainable treatment.
Methods
We conducted a narrative review of PubMed/MEDLINE, Embase, and Cochrane Library publications through 2026. Pediatric clinical studies, systematic reviews, meta-analyses, and international guidelines addressing dietary, pharmacological, and biologic therapies were qualitatively synthesized, with selected adult evidence included when pediatric data were unavailable.
Results
Empiric elimination diets remain effective first-line options, with step-up strategies reducing unnecessary restriction and treatment burden. Elemental diets achieve histological remission in more than 90% of patients but are limited by palatability, cost, and adherence. Allergy test-directed diets have low predictive value and are not routinely recommended. Proton pump inhibitors and swallowed topical corticosteroids are established first-line therapies with favorable safety profiles. Real-world evidence suggests that treatment choice depends on age, phenotype, local practice, and family preference, whereas comparative effectiveness data remain limited. Dupilumab, the first biologic approved for EoE, produces substantial histological and endoscopic improvement across pediatric age groups and is particularly relevant for difficult-to-control disease or coexisting type 2 conditions. Other targeted agents reduce eosinophilia, but symptomatic benefit and pediatric evidence remain inconsistent.
Conclusions
Pediatric EoE management should combine shared decision-making with objective histological monitoring and attention to growth, nutrition, adherence, and quality of life. Future research should define optimal treatment sequencing and maintenance, validate noninvasive biomarkers, and establish the long-term safety and effectiveness of emerging therapies in diverse pediatric populations and clinical settings.
Zitieren
APA
Natale, M., Ientile, L., Palazzolo, E., Mucci, B., & Esposito, S. (2026). Management of Pediatric Eosinophilic Esophagitis: Current Therapies, Emerging Treatments, and Future Directions—A Narrative Review. Pharmaceuticals, 19(11), 1685. https://doi.org/10.3390/ph19111685
Vancouver
Natale M, Ientile L, Palazzolo E, Mucci B, Esposito S. Management of Pediatric Eosinophilic Esophagitis: Current Therapies, Emerging Treatments, and Future Directions—A Narrative Review. Pharmaceuticals. 2026;19(11):1685. doi:10.3390/ph19111685
BibTeX
@article{Natale2026,
author = {Natale, Marco and Ientile, Lorenzo and Palazzolo, Elisabetta and Mucci, Benedetta and Esposito, Susanna},
title = {Management of Pediatric Eosinophilic Esophagitis: Current Therapies, Emerging Treatments, and Future Directions—A Narrative Review},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1685},
doi = {10.3390/ph19111685}
}
EUVIMED